Randomized double blind trial for inhibitory effect of sulindac and etodorac on aberrant crypt foci (ACF)

Randomized double blind trial for inhibitory effect of sulindac and etodorac on aberrant crypt foci (ACF) - Randomized double blind trial for inhibitory effect of sulindac and etodorac on ACF

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000100

Enrollment

360

Registered

2005-09-10

Start date

2002-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjects with aberrant crypt foci(ACF)

Interventions

Oral administration of sulindac 150mg twice daily for 8 weeks Oral administration of etodorac 200mg twice daily for 8 weeks Oral administration of lactose 200mg twice daily for 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Obtaining informed consent 2)Positive for ACF 3)Negative for polyps (including polypectomized colon) 4)WBC more than 4000/mm3 5)Platlet more than 100,000/mm3 6)BUN less than 25 mg/dl 7)GOT and GPT within 2.5-fold normal limit 8)Total bilirubin less than 2.0mg/dl

Exclusion criteria

Exclusion criteria: 1)Intake of NSAIDs for more than 1 week within the last 2 months 2)pregnant 3)Posibility of becoming pregnant in the study period 4)Active gastrointestinal ulcer 5)Cancer (except for complete cure) 6)Active infection 7)Allergy for sulindac or etodorac

Design outcomes

Primary

Measure	Time frame
Observation of ACF and polyp using magnifying endoscopy	—

Countries

Japan

Contacts

Public ContactTetsuji Takayama

Sapporo Medical University School of Medicine 4th Department of Internal Medicine

011-611-2111(3254)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026